Top Page
kneat.com
(TSX:KSI)
kneat.com (KSI) vs. iShares MSCI Canada ETF (EWC)
kneat.com Business Overview & Revenue Model
kneat.com Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 52.92M | 48.94M | 34.22M | 23.75M | 15.50M | 7.42M | Gross Profit |
| 39.75M | 36.76M | 23.13M | 14.65M | 9.32M | 2.88M | EBIT |
| -5.10M | -5.95M | -13.53M | -9.77M | -6.35M | -6.56M | EBITDA |
| 12.78M | 6.27M | -5.77M | -3.20M | -5.11M | -2.30M | Net Income Common Stockholders |
| -2.24M | -7.73M | -14.12M | -9.15M | -9.86M | -5.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.25M | 58.89M | 15.25M | 12.28M | 21.56M | 8.66M | Total Assets |
| 64.50M | 124.58M | 64.50M | 50.41M | 51.28M | 33.80M | Total Debt |
| 28.17M | 29.26M | 28.17M | 7.09M | 7.86M | 9.52M | Net Debt |
| 12.92M | -29.63M | 12.92M | -5.19M | -13.70M | 860.92K | Total Liabilities |
| 49.73M | 59.51M | 49.73M | 24.43M | 17.09M | 14.59M | Stockholders Equity |
| 14.76M | 65.07M | 14.76M | 25.98M | 34.19M | 19.21M |
| Cash Flow | Free Cash Flow | ||||
| -1.71M | -10.09M | -18.39M | -9.82M | -7.74M | -9.28M | Operating Cash Flow |
| 18.86M | 9.79M | -1.28M | 2.99M | 2.31M | -1.98M | Investing Cash Flow |
| -16.37M | -17.52M | -15.97M | -11.91M | -10.04M | -6.43M | Financing Cash Flow |
| 31.64M | 50.62M | 20.27M | -383.91K | 21.20M | 13.11M |
kneat.com Technical Analysis
kneat.com Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | C$554.50M | 192.34 | 2.15% | ― | 35.97% | -59.04% | |
68 Neutral | C$622.08M | ― | -4.56% | ― | 42.93% | 85.95% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
52 Neutral | C$19.07M | ― | -244.35% | ― | -71.31% | -53.11% | |
34 Underperform | C$22.51M | ― | -9999.00% | ― | ― | -50.06% | |
34 Underperform | $27.26M | ― | ― | -171.18% | 46.80% | ||
24 Underperform | C$23.43M | ― | 366.78% | ― | -35.15% | -6.59% |
kneat.com Earnings Call Summary
kneat.com Corporate Events
Kneat.com has announced a significant three-year Master Services Agreement with a major U.S.-based manufacturer of clinical diagnostics, which operates globally. This agreement will see the diagnostics company initially use Kneat’s digital platform, Kneat Gx, to digitize its equipment validation process, reflecting a broader industry trend towards digitalization for improved quality and compliance. This partnership underscores Kneat’s market position as a leader in digital validation solutions, promising enhanced efficiency and compliance benefits for its clients.
The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.
Kneat.com announced record revenue for the first quarter of 2025, with total revenue reaching $14.7 million, marking a 37% increase year over year. The company also reported a significant rise in Annual Recurring Revenue and gross profit, indicating strong growth and progress toward profitability. Recent strategic partnerships and client acquisitions in the life sciences sector, along with the expansion of its executive team, underscore Kneat’s commitment to scaling its operations and enhancing its market position.
Kneat.com has announced an expansion of its executive leadership team to enhance product innovation and strategic planning. Kevin Fitzgerald, co-founder and current Chief Product Officer, will transition to the role of Chief Innovation Officer, focusing on strategic vision and product innovation. Donal O’Sullivan, with over 25 years of experience in software development leadership, will join as the new Chief Product Officer. This leadership change aims to strengthen Kneat’s position in the market by optimizing product excellence and capturing growth opportunities.
Kneat.com announced it will release its first-quarter financial results for 2025 on May 7, after the TSX market closes. The company will host a webcast conference call on May 8, led by CEO Eddie Ryan and CFO Hugh Kavanagh, to discuss the results with analysts. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially influencing market perceptions and investment decisions.
Kneat.com has signed a Services Agreement with a major multinational generic pharmaceuticals producer to digitalize its drawing management process, enhancing the efficiency and accuracy of engineering and validation processes. This collaboration highlights Kneat’s strong market positioning and its ability to attract leading global companies, further solidifying its reputation in the life sciences industry as a provider of choice for digital validation solutions.
Kneat.com reported record financial results for the fourth quarter and full year of 2024, with significant revenue growth and improved profitability. The company’s total revenue for the fourth quarter reached $13.7 million, marking a 40% year-over-year increase, while its annual recurring revenue grew by 60% to $59.7 million. The company’s strategic expansion included the addition of five large customers and the formalization of its partner program, which now includes major partners like Körber and ALTEN Group. These developments underscore Kneat’s robust business model and its leading role in the digital transformation of validation processes within the life sciences industry.
Kneat.com announced it will release its financial results for the fourth quarter and full year of 2024 on February 26, 2025. The announcement will be followed by a webcast hosted by the CEO and CFO for sell-side analysts. This release is significant as it provides stakeholders with insights into the company’s financial health and performance, potentially impacting its market positioning and investor relations.